Currently, only a few biomarkers are used for therapy stratification in BC patients (e.g., ER, HER2), whereas biomarkers predictive of treatment response will contribute to further tailoring and improving BC treatment, i.e., avoiding toxic therapy for those not benefiting of it. This evidence concerns the gene ESR1 and breast cancer.